Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 1 · 33.3%

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Progression‐free survival · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.89 [0.81, 0.98]
4 studies · 3699 participants
Moderate

Gefitinib vs tri‐weekly paclitaxel plus carboplatin

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.39 [0.32, 0.48]
2 studies · 485 participants
High

Gefitinib vs pemetrexed + carboplatin with pemetrexed maintenance

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.59 [0.46, 0.74]
2 studies · 371 participants
Moderate